These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

302 related items for PubMed ID: 10978394

  • 1. Urinary excretion of podocytes in patients with diabetic nephropathy.
    Nakamura T, Ushiyama C, Suzuki S, Hara M, Shimada N, Ebihara I, Koide H.
    Nephrol Dial Transplant; 2000 Sep; 15(9):1379-83. PubMed ID: 10978394
    [Abstract] [Full Text] [Related]

  • 2. Effects of angiotensin-converting enzyme inhibitor, angiotensin II receptor antagonist and calcium antagonist on urinary podocytes in patients with IgA nephropathy.
    Nakamura T, Ushiyama C, Suzuki S, Hara M, Shimada N, Sekizuka K, Ebihara I, Koide H.
    Am J Nephrol; 2000 Sep; 20(5):373-9. PubMed ID: 11092994
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Epithelial-mesenchymal transition as a potential explanation for podocyte depletion in diabetic nephropathy.
    Yamaguchi Y, Iwano M, Suzuki D, Nakatani K, Kimura K, Harada K, Kubo A, Akai Y, Toyoda M, Kanauchi M, Neilson EG, Saito Y.
    Am J Kidney Dis; 2009 Oct; 54(4):653-64. PubMed ID: 19615802
    [Abstract] [Full Text] [Related]

  • 8. Pioglitazone reduces urinary podocyte excretion in type 2 diabetes patients with microalbuminuria.
    Nakamura T, Ushiyama C, Osada S, Hara M, Shimada N, Koide H.
    Metabolism; 2001 Oct; 50(10):1193-6. PubMed ID: 11586492
    [Abstract] [Full Text] [Related]

  • 9. The BErgamo NEphrologic DIabetes Complications Trial (BENEDICT): design and baseline characteristics.
    BENEDICT Group.
    Control Clin Trials; 2003 Aug; 24(4):442-61. PubMed ID: 12865039
    [Abstract] [Full Text] [Related]

  • 10. Urinary podocyte-associated mRNA profile in various stages of diabetic nephropathy.
    Zheng M, Lv LL, Ni J, Ni HF, Li Q, Ma KL, Liu BC.
    PLoS One; 2011 Aug; 6(5):e20431. PubMed ID: 21655212
    [Abstract] [Full Text] [Related]

  • 11. Periostin as a tissue and urinary biomarker of renal injury in type 2 diabetes mellitus.
    Satirapoj B, Tassanasorn S, Charoenpitakchai M, Supasyndh O.
    PLoS One; 2015 Aug; 10(4):e0124055. PubMed ID: 25884625
    [Abstract] [Full Text] [Related]

  • 12. Urinary podocalyxin is an early marker for podocyte injury in patients with diabetes: establishment of a highly sensitive ELISA to detect urinary podocalyxin.
    Hara M, Yamagata K, Tomino Y, Saito A, Hirayama Y, Ogasawara S, Kurosawa H, Sekine S, Yan K.
    Diabetologia; 2012 Nov; 55(11):2913-9. PubMed ID: 22854890
    [Abstract] [Full Text] [Related]

  • 13. Dual therapy versus monotherapy of trandolapril and telmisartan on diabetic nephropathy in experimentally induced type 2 diabetes mellitus rats.
    Rao RP, Jain A, Srinivasan B.
    J Renin Angiotensin Aldosterone Syst; 2011 Sep; 12(3):169-75. PubMed ID: 21421651
    [Abstract] [Full Text] [Related]

  • 14. A Liquid-Based Cytology System, without the Use of Cytocentrifugation, for Detection of Podocytes in Urine Samples of Patients with Diabetic Nephropathy.
    Kimura M, Toyoda M, Saito N, Kaneyama N, Miyatake H, Tanaka E, Komaba H, Hara M, Fukagawa M.
    J Diabetes Res; 2019 Sep; 2019():9475637. PubMed ID: 30911554
    [Abstract] [Full Text] [Related]

  • 15. ACE-inhibitors but not endothelin receptor blockers prevent podocyte loss in early diabetic nephropathy.
    Gross ML, El-Shakmak A, Szábó A, Koch A, Kuhlmann A, Münter K, Ritz E, Amann K.
    Diabetologia; 2003 Jun; 46(6):856-68. PubMed ID: 12802493
    [Abstract] [Full Text] [Related]

  • 16. Urine synaptopodin excretion is an important marker of glomerular disease progression.
    Kwon SK, Kim SJ, Kim HY.
    Korean J Intern Med; 2016 Sep; 31(5):938-43. PubMed ID: 27604800
    [Abstract] [Full Text] [Related]

  • 17. Increased Urinary Excretion of Podocyte Markers in Normoalbuminuric Patients with Diabetes.
    Lioudaki E, Stylianou KG, Petrakis I, Kokologiannakis G, Passam A, Mikhailidis DP, Daphnis EK, Ganotakis ES.
    Nephron; 2015 Sep; 131(1):34-42. PubMed ID: 26340089
    [Abstract] [Full Text] [Related]

  • 18. Urinary excretion of advanced glycation endproducts in patients with type 2 diabetes and various stages of proteinuria.
    Turk N, Mornar A, Mrzljak V, Turk Z.
    Diabetes Metab; 2004 Apr; 30(2):187-92. PubMed ID: 15223992
    [Abstract] [Full Text] [Related]

  • 19. Urinary heme oxygenase-1 as a potential biomarker for early diabetic nephropathy.
    Li Z, Xu Y, Liu X, Nie Y, Zhao Z.
    Nephrology (Carlton); 2017 Jan; 22(1):58-64. PubMed ID: 26733347
    [Abstract] [Full Text] [Related]

  • 20. Urinary excretion of podocytes reflects disease activity in children with glomerulonephritis.
    Hara M, Yanagihara T, Takada T, Itoh M, Matsuno M, Yamamoto T, Kihara I.
    Am J Nephrol; 1998 Jan; 18(1):35-41. PubMed ID: 9481437
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.